Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Advanced Cancers × Vorinostat × Clear all

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 3 Neoplasms, Plasma Cell 2 Mycosis Fungoides 2 Lymphoma, T-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell 2 Burkitt Lymphoma 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sezary Syndrome 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Mesothelioma, Malignant 1 Mesothelioma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Carcinoma, Squamous Cell 1 Breast Neoplasms 1 Advanced Cancers 1

Interventions

X-Rays 1 Vorinostat 1 Sorafenib 1 Magnetic Resonance Spectroscopy 1 Erlotinib Hydrochloride 1 Curcumin 1 Cetuximab 1 AH 111585 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡